Abstracts tagged "Data analysis"

Abstract Number: 532 • 2016 ACR/ARHP Annual Meeting
The DAS28 Score May Misread Disease Activity in Rheumatoid Arthritis Patients
Abdul Khan¹ and Apostolos Vrettos², ¹Rheumatology, East Kent University Hospital NHS Foundation Trust, Queen Elizabeth Queen Mother Hospital, Margate, United Kingdom, ²Rheumatology, Queen Elizabeth Queen Mother Hospital, Margate, United Kingdom
Background/Purpose: The DAS28 is a measure of disease activity in rheumatoid arthritis (RA). DAS28 stands for 'disease activity score' and the number 28 refers to…
Abstract Number: 912 • 2016 ACR/ARHP Annual Meeting
Urate Lowering Therapy in Moderate to Severe Chronic Kidney Disease
Gerald D. Levy^1,2, Craig Cheetham³, Nazia Rashid⁴ and Jiaxiao Shi³, ¹Internal Medicine/Rheumatology, Southern California Kaiser Permanente, Downey, CA, ²Rheumatology, Kaiser Permanente Southern California, Downey, CA, ³Research and Evaluation, Southern California Medical Group, Pasadena, CA, ⁴Pharmacy Analytic Services, Kaiser Permanente, Downey, CA
Urate Lowering Therapy in Moderate to Severe Chronic Kidney Disease Levy G, Cheetham C, Shi J, Rashid N Background/Purpose: To determine if urate lowering…
Abstract Number: 1945 • 2016 ACR/ARHP Annual Meeting
Development and Validation of Case-Finding Algorithms for the Identification of Patients with ANCA-Associated Vasculitis and Large-Vessel Vasculitis in Healthcare Administrative Databases
Antoine G. Sreih¹, Narender Annapureddy², Jason Springer³, Kevin Byram⁴, George Casey⁵, Andy Cruz⁶, Maya Estephan⁷, Vince Frangiosa⁸, Michael D. George⁸, Mei Liu⁹, Mehrdad Maz¹⁰, Adam Parker⁷, Sapna Sangani¹¹, Rebecca Sharim¹² and Peter A. Merkel¹³, ¹Rheumatology, The University of Pennsylvania, Philadelphia, PA, ²Vanderbilt University, Nashville, TN, ³Department of Internal Medicine, Division of Allergy, Clinical Immunology, & Rheumatology, Kansas University Medical Center, Kansas City, KS, ⁴Internal Medicine, Vanderbilt University, Nashville, TN, ⁵The Vasculitis Foundation, Kansas City, MO, ⁶Informational Technology, The University of Pennsylvania, Philadelphia, PA, ⁷Rheumatology, The University of Kansas, Kansas City, KS, ⁸Rheumatology, University of Pennsylvania, Philadelphia, PA, ⁹Informational Technology, The University of Kansas, Kansas City, KS, ¹⁰Allergy, Clinical Immunology, and Rheumatology, The University of Kansas Medical Center, Department of Internal Medicine, Division of Allergy, Clinical Immunology and Rheumatology, Kansas City, KS, ¹¹Penn Vasculitis Center, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ¹²Rheumatology, Temple University, Philadelphia, PA, ¹³Division of Rheumatology, University of Pennsylvania, Philadelphia, PA
Background/Purpose: ANCA-associated vasculitis (AAV) is a group of vasculitides that consists of granulomatosis with polyangiitis (GPA), eosinophilic granulomatosis with polyangiitis (Churg-Strauss; EGPA), and microscopic polyangiitis…
Abstract Number: 2358 • 2016 ACR/ARHP Annual Meeting
High-Fat Diet Is Associated with a Higher Incidence of Radiographic Knee OA and Progression of Knee Joint Space Narrowing: Data from the Osteoarthritis Initiative
Anna Shmagel¹, Naoko Onizuka², Lisa Langsetmo³, Kristine E. Ensrud⁴ and Robert Foley⁵, ¹Rheumatic & Autoimmune Diseases, University of Minnesota, Minneapolis, MN, ²University of Minnesota, Minneapolis, MN, ³University of Minnesota School of Public Health, Minneapolis, MN, ⁴University of Minnesota and Minneapolis VAHS, Minneapolis, MN, Minneapolis, MN, ⁵Renal Diseases and Hypertension, University of Minnesota, Minneapolis, MN
Background/Purpose: Animal studies have shown that high-fat diet may increase the risk of osteoarthritis (OA), while other evidence suggests that dietary polyunsaturated fatty acids may…
Abstract Number: 2470 • 2016 ACR/ARHP Annual Meeting
Treat to Target: Theoretical Agreement Vs Daily Applicability
Leonardo Romeiro¹, Dalton Torigoe², Claiton Brenol³, Roberto Ranza⁴, Lícia M. H. Mota⁵, Manoel Bertolo⁶, Max Freitas⁷, José Tupinambá⁸, Ivanio Pereira⁹, Lucila Fronza¹⁰ and Ieda Maria Magalhães Laurindo¹¹, ¹Rheumatology, UNESA, Rio de Janeiro, Rio de Janeiro, Brazil, ²Faculdade de Medicina da Santa Casa de Misericordia, São Paulo, Brazil, ³Rua Cabral, 764 – Apto 302, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, ⁴Reumatologia, Reumatologia, Universidade Federal de Uberlandia, Uberlandia, Brazil, ⁵Hospital Universitário de Brasília - UnB, Brasília, Brazil, ⁶INTERNAL MEDICINE, DISCIPLINE OF RHEUMATOLOGY, Faculty of Medical Sciences, State University of Campinas (UNICAMP), Campinas, Brazil, ⁷Pathology, Federal University of Ceara, Fortaleza, Brazil, ⁸Universidade Federal do Piaui, Teresina, Brazil, ⁹Rheumatology, Universidade do Sul de Santa Catarina, Florianopolis, Brazil, ¹⁰CETI - Centro de Estudos em Terapias Inovadoras, Curitiba, Brazil, ¹¹Internal Medicine - Rheumatology, Faculdade de Medicina da Universidade Nove de Julho, São Paulo, Brazil
Background/Purpose: Treat to target (T2T) strategy has been widely recognized as effective and leading to better outcomes. There have been no questions regarding its theoretical…
Abstract Number: 149 • 2015 ACR/ARHP Annual Meeting
Characteristics of Patients Diagnosed with Systemic Lupus Erythematosus (SLE) Initiating Treatment with Belimumab in a US Commercially Insured Database: 2010-2014
Deanna Hill¹, Hong Kan², Peter Egger³, David J. Chang⁴, Amanda Eudy^1,5, Joe Maskell³ and Karen H. Costenbader⁶, ¹Worldwide Epidemiology, GlaxoSmithKline, Collegeville, PA, ²Value Evidence and Outcomes, GlaxoSmithKline, Research Triangle Park, NC, ³Worldwide Epidemiology, GlaxoSmithKline, Stockley Park, United Kingdom, ⁴US Medical Affairs, GlaxoSmithKline, Philadelphia, PA, ⁵Gillings School of Global Public Health, University of North Carolina, Chapel Hill, NC, ⁶Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Belimumab, a B-lymphocyte stimulator, was FDA-approved March 2011 for the treatment of adult patients with active, autoantibody-positive SLE receiving standard of care (SOC) medications.…
Abstract Number: 828 • 2015 ACR/ARHP Annual Meeting
Development of a Disease Damage Index in Systemic Sclerosis Using Consensus and Data Driven Methods
Nava Ferdowsi¹, Molla Huq¹, Jodie Burchell², Sam Mancuso², Tien Tay^1,3, Wendy Stevens⁴, Candice Rabusa⁴, Marie Hudson⁵, Vijaya Sundararajan², David Prior⁶, Susanna Proudman⁷, Murray Baron⁸ and Mandana Nikpour^9,10, ¹Rheumatology, The University of Melbourne at St Vincent’s Hospital, Melbourne, Australia, ²Medicine, The University of Melbourne at St Vincent’s Hospital, Melbourne, Australia, ³41 Victoria Parade, Fitzroy, St Vincent's Hospital, Melbourne, Australia, ⁴Rheumatology, St. Vincent’s Hospital, Melbourne, Australia, ⁵Medicine, McGill University, Montreal, QC, Canada, ⁶Cardiology, St Vincent's Hospital, Melbourne, Australia, ⁷Rheumatology Unit, Royal Adelaide Hospital North Terrace, Adelaide, Australia, ⁸Rheumatology, McGill University, Jewish General Hospital, Montreal, QC, Canada, ⁹St Vincent's Hospital, Melbourne, Australia, ¹⁰Medicine, The University of Melbourne at St. Vincent’s Hospital, Melbourne, Australia
Background/Purpose: As there is currently no existing index for quantifying organ damage in systemic sclerosis (SSc), we sought to develop a disease damage index in…
Abstract Number: 3173 • 2015 ACR/ARHP Annual Meeting
Premature Mortality Due to Fractures in a Population-Based Prospective Cohort Study of 238,673 Older Women and Men
Lyn March¹, Weiwen Chen², Judy M Simpson³, Fiona Blyth⁴ and Jacqueline Center², ¹Department of Rheumatology, Northern Clinical School, Institute of Bone and Joint Research, Kolling Institute, University of Sydney & Department of Rheumatology, Royal North Shore Hospital, St Leonards, Sydney, Australia, ²Endocrinology, Osteoporosis & Bone Biology Garvan Institute of Medical Research, St Vincent's Clinical School, UNSW, Darlinghurst, Australia, ³Statistics, University of Sydney School of Public Health, Sydney, Australia, ⁴Concord Clinical School University of Sydney and Sax Institute, Sydney, Australia
Background/Purpose: Osteoporotic (OP) fractures and falls are a growing global problem as the population ages. One third of all falls related deaths are attributable to…
Abstract Number: 2429 • 2014 ACR/ARHP Annual Meeting
Seasonal Changes May Influence Activity of Rheumatoid Arthritis
Ryuji Nagamine, Bone and Joint Center, Sugioka Memorial Hospital, Fukuoka, Japan
Background/Purpose: RA activity during the year was assessed to investigate whether seasonal changes influenced parameters of RA activity. Methods: This study was performed in Fukuoka,…
Abstract Number: 2076 • 2014 ACR/ARHP Annual Meeting
Predictive Modeling of a Fibromyalgia Diagnosis: Increasing the Accuracy Using Real World Data
Birol Emir¹, Jack Mardekian¹, Elizabeth T. Masters¹, Andrew Clair¹, Max Kuhn² and Stuart L. Silverman³, ¹Pfizer Inc, New York, NY, ²Pfizer Inc., Groton, CT, ³Cedars-Sinai Medical Center, UCLA Center of Excellence, Los Angeles, CA
Background/Purpose: The number of symptoms and comorbidities associated with the chronic pain condition of fibromyalgia (FM) complicates its identification and diagnosis. Methods: This retrospective analysis…
Abstract Number: 1882 • 2014 ACR/ARHP Annual Meeting
Examination of Patients Newly Diagnosed with Fibromyalgia: Use of Guideline-Recommended Therapies and Opioids in Clinical Practice
Sonali N. Shah¹, Rachel Halpern², Joseph C. Cappelleri³, Elizabeth T. Masters⁴, Andrew G. Clair⁵, Cori Blauer-Peterson² and Damon Van Voorhis⁶, ¹Health Economics and Outcomes Research, Pfizer, Inc., New York, NY, ²Health Economics and Outcomes Research, Optum, Eden Prairie, MN, ³Biostatistics, Pfizer, Inc., Groton, CT, ⁴Health Economics and Outcomes Research, Pfizer Inc, New York, NY, ⁵US Medical Affairs Primary Care, Pfizer, Inc., New York, NY, ⁶Optum Life Sciences, Eden Prairie, MN
Background/Purpose: Fibromyalgia (FM) affects 2-5% of adults in the United States. Pregabalin (antiepileptic drug [AED]), and duloxetine and milnacipran (serotonin and norepinephrine reuptake inhibitors), are…
Abstract Number: 1165 • 2014 ACR/ARHP Annual Meeting
Evaluation of Symptom Control Among Treated Gout Patients in the United States, United Kingdom, and Germany
Robert Morlock¹, Chris Storgard², Vernon F. Schabert³, Augustina Ogbonnaya³, Pierre Chevalier⁴, Dionne Hines³ and Sulabha Ramachandran⁵, ¹4939 Directors Place, Ardea Biosciences, San Diego, CA, ²Ardea Biosciences, Inc., San Diego, CA, ³IMS Health, Alexandria, VA, ⁴IMS Health, Vilvoorde, Belgium, ⁵AstraZeneca, Wilmington, DE
Background/Purpose: Gout affects approximately 1-4% of the population in developed Western countries. The hallmark signs of gout are elevated serum uric acid (SUA) level, episodes…
Abstract Number: 227 • 2014 ACR/ARHP Annual Meeting
Increasing Fat-Mass May Reverse Bone Loss As Detected By DXA Scan
William Hedges¹ and Marwan Bukhari^2,3, ¹Foundation Programme, Royal Lancaster Infirmary, University Hospitals of Morecambe Bay NHS Foundation Trust, Lancaster, United Kingdom, ²Lancaster Medical School, Lancaster University, Lancaster, United Kingdom, ³Rheumatology, Royal Lancaster Infirmary, Lancaster, United Kingdom
Background/Purpose: Low body mass index (BMI) is a known risk factor for loss of bone mineral density (BMD). It is a part of the FRAX…
Abstract Number: 2534 • 2013 ACR/ARHP Annual Meeting
Pregnancy Complications In Lupus: Retrospective Observational Analysis From a US Health Claims Database
Michelle. A. Petri¹, Paola Daly², Daphnee S. Pushparajah³, David Friesen⁴ and Lydia Makaroff³, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Lupus Foundation of America, Washington DC, DC, ³UCB Pharma, Brussels, Belgium, ⁴UCB Pharma, Slough, United Kingdom
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex autoimmune disease most frequently affecting women of childbearing age. Women with SLE are known to be at…
Abstract Number: 2139 • 2013 ACR/ARHP Annual Meeting
Do Hyaluronic Acid Injections Delay Total Knee Replacement Surgery?
Thomas Abbott¹, Roy D. Altman², Robert Dimeff³, Michael Fredericson⁴, Vijay Vad⁵, Peter Vitanzo Jr.⁶, Sashi Yadalam¹, Ronald Levine¹, Brad Bisson⁷ and Samir Bhattacharyya⁷, ¹Johnson & Johnson, New Brunswick, NJ, ²David Geffen School of Medicine, UCLA, Los Angeles, CA, ³UT Southwestern Medical Center, Dallas, TX, ⁴Stanford University School of Medicine, Menlo Park, CA, ⁵Weill Cornell Medical College, NY, NY, ⁶Rothman Institute, Philadelphia, PA, ⁷DePuy Synthes Mitek Sports Medicine, Raynham, MA
Background/Purpose: More than 27 million adults in the US have knee osteoarthritis (OA), a painful and life-altering disease. Various non-pharmacologic and pharmacologic agents are recommended…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].